PTAB Upholds Broad Institute's CRISPR Patent Priority in Latest Ruling

The Patent Trial and Appeal Board (PTAB) has upheld the Broad Institute's priority claim in its ongoing CRISPR-Cas9 patent dispute with the University of California, reinforcing the Broad's control over key eukaryotic gene editing intellectual property. The March 28, 2026 decision maintains the status quo in a patent battle that has shaped the $7.2 billion gene editing market for over a decade.

The ruling specifically affirms the Broad Institute's patents covering CRISPR applications in eukaryotic cells—the foundation for most therapeutic applications including CAR-T cell engineering and in vivo gene therapies. This decision protects patent coverage that expires between 2031-2033, giving the Broad continued licensing leverage over companies developing CRISPR-based treatments.

The University of California, led by Jennifer Doudna and Emmanuelle Charpentier's foundational work, had challenged the Broad's priority claims through interference proceedings. However, PTAB found that Feng Zhang's team at the Broad demonstrated sufficient evidence of conception and reduction to practice for eukaryotic CRISPR systems before UC's patent applications.

## What This Means for the Synthetic Biology Industry

The PTAB decision crystallizes a patent landscape that has already guided billions in licensing deals and M&A activity. Companies like Mammoth Biosciences, Caribou Biosciences, and Synthego have built business models around navigating this divided patent estate.

The Broad Institute's Editas Medicine holds exclusive rights to certain Broad patents for therapeutic applications, while UC Berkeley's Innovative Genomics Institute has licensed broadly to academic institutions and some commercial entities. This dual licensing structure has created parallel development pathways in the CRISPR ecosystem.

Most significantly for synthetic biology applications, the ruling maintains certainty around foundational IP that underpins cell therapy manufacturing, agricultural biotechnology, and industrial biomanufacturing processes. Companies engineering chassis organisms or developing complex gene circuits can continue operating under existing licensing frameworks without patent cloud uncertainty.

## Market Impact and Licensing Dynamics

The decision preserves a patent licensing ecosystem worth an estimated $2.8 billion annually across therapeutic and industrial applications. The Broad Institute has generated over $180 million in CRISPR licensing revenue since 2014, while UC's licensing arm has collected approximately $145 million through more permissive academic and commercial licenses.

For emerging companies in synthetic biology, this ruling means continued navigation of overlapping patent claims. Early-stage biotechs typically budget $150,000-$400,000 annually for CRISPR patent licensing, depending on application scope and commercialization timeline. Later-stage companies face milestone payments ranging from $2-15 million plus royalties of 1-4% on net sales.

The pharmaceutical industry has largely adapted to this bifurcated patent landscape. Vertex Pharmaceuticals paid $875 million upfront to access Editas Medicine's Broad Institute licenses for CTX001, their sickle cell gene therapy. Meanwhile, companies working with UC-licensed CRISPR tools often face lower upfront costs but higher downstream royalty obligations.

## Technical Implications for Gene Editing Applications

The PTAB ruling specifically covers patents related to CRISPR delivery in mammalian cells, guide RNA design optimization, and multiplexed editing approaches. These patents remain essential for most therapeutic applications where editing efficiency above 30% is required and off-target rates must stay below 0.1%.

Companies developing next-generation editing tools like base editing systems or prime editing platforms still require foundational CRISPR licenses. David Liu's base editing patents at the Broad Institute, for example, build upon the core Cas9 patent estate upheld in this decision.

The ruling also affects industrial synthetic biology applications where CRISPR is used for metabolic engineering. Companies like Ginkgo Bioworks and others developing automated biofoundry platforms rely on high-throughput CRISPR workflows covered by Broad patents for pathway optimization and strain development.

## Looking Ahead: Patent Cliff and Next-Generation Tools

With core CRISPR patents beginning to expire in 2031, the industry is already positioning for a post-patent landscape. The Broad Institute has filed continuation applications covering CRISPR improvements and delivery methods that could extend patent protection into the late 2030s. However, newer editing modalities like prime editing, CRISPR 3.0 systems, and epigenome editing tools represent the next competitive frontier.

Companies are increasingly investing in CRISPR alternatives and improvements to reduce dependence on foundational patents. Chroma Medicine's epigenetic editing platform and various nuclease-free editing approaches represent attempts to innovate around existing patent barriers while the core IP remains active.

## Key Takeaways

  • PTAB affirmed Broad Institute's priority for eukaryotic CRISPR patents, maintaining current licensing landscape
  • Decision affects $7.2 billion gene editing market and preserves dual licensing structure between Broad and UC systems
  • Companies continue facing $150K-$400K annual licensing costs for early-stage applications
  • Core patents expire 2031-2033, driving innovation in next-generation editing tools
  • Industrial synthetic biology applications remain dependent on Broad patent estate for high-efficiency editing

## Frequently Asked Questions

Does this ruling change existing CRISPR licensing agreements? No, the PTAB decision maintains the status quo. Companies with existing licenses from either the Broad Institute or UC system continue operating under current terms. The ruling prevents UC from challenging priority and potentially disrupting established licensing frameworks.

Which companies are most affected by this patent decision? Therapeutic companies using CRISPR for CAR-T cell engineering, gene therapy developers, and industrial biotechnology firms using CRISPR for metabolic engineering face the most direct impact. Companies like Editas Medicine benefit from continued exclusive access to certain Broad patents.

When will core CRISPR patents expire and what happens then? The foundational Broad Institute CRISPR patents expire between 2031-2033. After expiration, the basic CRISPR-Cas9 technology becomes freely available for commercial use, though newer improvements and delivery methods may remain patent-protected.

How does this affect academic research using CRISPR? Academic research generally continues under existing licensing terms. UC Berkeley has provided broad academic licenses, while the Broad Institute offers academic licensing through various programs. The ruling doesn't change academic access to CRISPR tools.

What alternatives exist to avoid CRISPR patent licensing? Companies can develop using CRISPR alternatives like base editing, prime editing, or newer nuclease systems. However, most high-efficiency applications still require access to foundational CRISPR patents for optimal performance.